QTTB on Nasdaq
Q32 Bio Inc.
American pharmaceutical preparations company, incorporated in Delaware.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Agios Pharmaceuticals, Nektar Therapeutics or OCULAR THERAPEUTIX, INC, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development36¢$19.2M
- Other costs9¢$4.8M
- Profit55¢$29.8M
Out of $53.7M in revenue.3
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration arrangement revenue | $53.7M | $0 |
| Research and development | $19.2M | $48.1M |
| General and administrative | $17.7M | $18.0M |
| Total operating expenses | $36.8M | $66.1M |
| Income (loss) from operations | $16.9M | -$66.1M |
| Change in fair value of convertible notes | $0 | $15.9M |
| Gain on sale of asset | $11.7M | $0 |
| Other income (expense), net | $1.2M | $4.1M |
| Total other income (expense), net | $12.9M | $20.0M |
| Income (loss) before provision for income taxes and loss from equity method investment | $29.8M | -$46.1M |
| Provision for income taxes | $0 | -$21.0K |
| Loss from equity method investment | $0 | -$1.6M |
| Net income (loss) | $29.8M | -$47.7M |
| Net income (loss) per share- basic | $2.42 | -$5.12 |
| Net income (loss) per share- diluted | $2.42 | -$6.58 |
| Weighted-average common shares - basic | 12.3M shares | 9.3M shares |
| Weighted-average common shares - diluted | 12.3M shares | 9.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-02-28 |
|---|---|---|---|---|
| Cash and cash equivalents | $48.3M | $78.0M | ||
| Prepaid expenses and other current assets | $6.8M | $3.9M | ||
| Total current assets | $55.0M | $81.9M | ||
| Equity investment | $0 | $2.6M | $74.1M | |
| Property and equipment, net | $979.0K | $1.4M | ||
| Right-of-use asset, operating leases | $5.1M | $5.7M | ||
| Restricted cash and restricted cash equivalents | $647.0K | $647.0K | ||
| Other noncurrent assets | $0 | $116.0K | ||
| Total assets | $61.8M | $92.3M | ||
| Accounts payable | $879.0K | $3.0M | ||
| Accrued expenses and other current liabilities | $4.2M | $7.5M | ||
| CVR liability | $0 | $2.9M | ||
| Venture debt, current portion | $6.2M | $3.1M | ||
| Total current liabilities | $11.3M | $16.5M | ||
| Lease liability, net of current portion | $4.9M | $5.6M | ||
| Venture debt, net of current portion | $3.5M | $9.6M | ||
| Other noncurrent liabilities | $0 | $55.0M | ||
| Total liabilities | $19.8M | $86.7M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.0001 par value; 400,000,000 shares authorized, 12,858,047 and 12,197,615 shares issued and outstanding at December 31, 2025 2024, respectively | $2.0K | $2.0K | ||
| Additional paid-in capital | $247.0M | $240.5M | ||
| Accumulated deficit | -$205.0M | -$234.8M | ||
| Total stockholders' equity (deficit) | $42.0M | $5.7M | -$182.9M | |
| Total liabilities and stockholders' equity (deficit) | $61.8M | $92.3M | ||
| Preferred stock par value per share | $0.00 | $0.00 | ||
| Preferred stock shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred Stock, Shares Outstanding | 0 shares | 0 shares | ||
| Preferred stock shares issued | 0 shares | 0 shares | ||
| Common stock, par value per share | $0.00 | $0.00 | ||
| Common stock, shares authorized | 400.0M shares | 400.0M shares | ||
| Common stock shares issued | 12.9M shares | 12.2M shares | ||
| Common stock shares outstanding | 12.9M shares | 12.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-02-28 |
|---|---|---|---|---|
| Cash and cash equivalents | $48.3M | $78.0M | ||
| Prepaid expenses and other current assets | $6.8M | $3.9M | ||
| Total current assets | $55.0M | $81.9M | ||
| Equity investment | $0 | $2.6M | $74.1M | |
| Property and equipment, net | $979.0K | $1.4M | ||
| Right-of-use asset, operating leases | $5.1M | $5.7M | ||
| Restricted cash and restricted cash equivalents | $647.0K | $647.0K | ||
| Other noncurrent assets | $0 | $116.0K | ||
| Total assets | $61.8M | $92.3M | ||
| Accounts payable | $879.0K | $3.0M | ||
| Accrued expenses and other current liabilities | $4.2M | $7.5M | ||
| CVR liability | $0 | $2.9M | ||
| Venture debt, current portion | $6.2M | $3.1M | ||
| Total current liabilities | $11.3M | $16.5M | ||
| Lease liability, net of current portion | $4.9M | $5.6M | ||
| Venture debt, net of current portion | $3.5M | $9.6M | ||
| Other noncurrent liabilities | $0 | $55.0M | ||
| Total liabilities | $19.8M | $86.7M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.0001 par value; 400,000,000 shares authorized, 12,858,047 and 12,197,615 shares issued and outstanding at December 31, 2025 2024, respectively | $2.0K | $2.0K | ||
| Additional paid-in capital | $247.0M | $240.5M | ||
| Accumulated deficit | -$205.0M | -$234.8M | ||
| Total stockholders' equity (deficit) | $42.0M | $5.7M | -$182.9M | |
| Total liabilities and stockholders' equity (deficit) | $61.8M | $92.3M | ||
| Preferred stock par value per share | $0.00 | $0.00 | ||
| Preferred stock shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred Stock, Shares Outstanding | 0 shares | 0 shares | ||
| Preferred stock shares issued | 0 shares | 0 shares | ||
| Common stock, par value per share | $0.00 | $0.00 | ||
| Common stock, shares authorized | 400.0M shares | 400.0M shares | ||
| Common stock shares issued | 12.9M shares | 12.2M shares | ||
| Common stock shares outstanding | 12.9M shares | 12.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss) | $29.8M | -$47.7M |
| Non-cash revenue from settlement of customer refund liability | -$53.7M | $0 |
| Amortization of debt discount and issuance costs | $180.0K | $194.0K |
| Amortization of premium on short-term investments | $0 | -$221.0K |
| Depreciation expense | $391.0K | $487.0K |
| Stock-based compensation expense | $5.3M | $4.4M |
| Non-cash lease expense | $622.0K | $579.0K |
| Loss from equity method investment | $0 | $1.6M |
| Loss on impairment of equity investment | $74.0K | $675.0K |
| Change in fair value of CVR liability | -$374.0K | -$2.2M |
| Change in fair value of convertible notes | $0 | -$15.9M |
| Gain on sale of asset | -$11.7M | $0 |
| Prepaid expenses and other current assets | $1.9M | $276.0K |
| Other noncurrent assets | $116.0K | $386.0K |
| Accounts payable | -$2.1M | -$1.0M |
| Operating lease liability | -$612.0K | -$1.5M |
| Accrued expenses and other current liabilities | -$3.3M | -$7.7M |
| Net cash used in operating activities | -$33.5M | -$67.7M |
| Purchases of property and equipment | $0 | -$75.0K |
| Proceeds from sale of asset | $7.0M | $0 |
| Maturities of short-term investments | $0 | $20.0M |
| Net cash provided by investing activities | $7.0M | $19.9M |
| Proceeds from borrowings under loan and security agreement | $0 | $7.0M |
| Proceeds from issuance of common stock in pre-closing financing | $0 | $42.0M |
| Cash acquired in connection with reverse recapitalization | $0 | $53.2M |
| Payment of reverse recapitalization transaction costs | $0 | -$8.7M |
| Principal payments on venture debt | -$3.1M | $0 |
| Proceeds from exercise of common stock options | $0 | $1.7M |
| Net cash provided by (used in) financing activities | -$3.1M | $95.1M |
| Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents | -$29.7M | $47.3M |
| Interest payments on venture debt | $961.0K | $856.0K |
| Issuance of common stock to Amgen at fair value | $1.3M | $0 |
| Short Term Investments Acquired In reverse recapitalization | $0 | $19.9M |
| Issuance of CVR at fair value | $0 | $180.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Q32 Bio Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerJodie Pope Morrison Mar 27, 2024 to now11
- Chief executive officerArthur Tzianabos Mar 27, 2018 to Feb 28, 202212
- PresidentLee Kalowski Mar 27, 2024 to now13
- PresidentArthur Tzianabos Mar 27, 2018 to Feb 28, 202212
- Chief financial officerLee Kalowski Mar 27, 2024 to now13
- Chief operating officerTimothy P. Kelly Apr 9, 2021 to Feb 28, 202214
- Chief operating officerSiyamak Rasty Mar 27, 2018 to Jul 11, 201915
Board members and other officers (26)
- Chief Medical OfficerJason Campagna Mar 27, 2024 to now16
- Chief Scientific OfficerShelia M. Violette Mar 27, 2024 to now17
- Chief Medical OfficerJulie Jordan Mar 16, 2023 to Aug 7, 202318
- OfficerCharles Michaud Jr. Nov 17, 2023 to Apr 23, 202419
- OfficerPaul Alloway Mar 11, 2022 to Apr 23, 202420
- Chief Medical OfficerGabriel Cohn Dec 3, 2019 to Jan 12, 202221
- Chief Scientific OfficerAlbert Seymour Mar 27, 2018 to Sep 8, 202322
- OfficerTimothy P. Kelly Sep 27, 2018 to Sep 8, 202123
- Board memberDavid S. Grayzel Mar 27, 2024 to now24
- Board memberDiyong Xu Mar 27, 2024 to now25
- Board memberIsaac Manke Mar 27, 2024 to now26
- Board memberJodie Pope Morrison Mar 27, 2024 to now11
- Board memberKathleen Laporte Mar 27, 2024 to now27
- Board memberMark T. Iwicki Mar 27, 2024 to now28
- Board memberSven Ante Lundberg Mar 27, 2024 to now29
- Board memberAlbert Seymour Sep 8, 2022 to Sep 8, 202330
- Board memberJeffrey Poulton V. Jul 21, 2020 to Jun 15, 202331
- Board memberAlise Reicin Jul 15, 2019 to Jun 15, 202332
- Board memberArthur Tzianabos Mar 27, 2018 to now12
- Board memberCameron Wheeler Mar 27, 2018 to Jun 11, 201933
- Board memberJames E. Flynn Mar 27, 2018 to Jun 11, 201934
- Board memberKush Parmar Mar 27, 2018 to Jun 17, 202235
- Board memberMahendra Shah Mar 27, 2018 to May 16, 201836
- Board memberMary Thistle Mar 27, 2018 to now37
- Board memberRichard J. Gregory Mar 27, 2018 to Jun 17, 202238
- Board memberMgmt Hif L.p. Deerfield Apr 4, 2018 to Apr 15, 201939
Former names
- Homology Medicines, Inc.Jan 6, 2016 to Mar 22, 20242
Timeline
Filings
339 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 52 major events, 153 insider forms, 34 large holders, 79 other. The latest 20:
- Oct 14, 20264 EDGAR
- Oct 14, 20264 EDGAR
- Oct 14, 20264 EDGAR
- Oct 9, 2026SCHEDULE 13G EDGAR
- Sep 30, 20268-K EDGAR
- Sep 14, 20268-K EDGAR
- Aug 27, 20264 EDGAR
- Aug 27, 20264 EDGAR
- Aug 27, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 31, 2026SCHEDULE 13G/A EDGAR
- Jul 28, 2026EFFECT EDGAR
- Jul 28, 2026424B3 EDGAR
- Jul 21, 20264/A EDGAR
- Jul 21, 20264/A EDGAR
- Jul 21, 20264/A EDGAR
- Jul 21, 20264/A EDGAR
The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 34 such filings since October 2021, the latest 10:
- Oct 9, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Jul 31, 2026SCHEDULE 13G/A
- Jul 20, 2026SCHEDULE 13D/A
- Jul 10, 2026SCHEDULE 13G
- Jul 6, 2026SCHEDULE 13G/A
- Jun 4, 2026SCHEDULE 13G
- Jun 4, 2026SCHEDULE 13G
- Jun 1, 2026SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 71. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Orbimed Advisors LLC | 4,127,987 | $52.6M | 1.0% | +1,875,000 |
| Boxer Capital Management, LLC | 3,149,310 | $40.1M | 3.0% | New |
| Atlas Venture Life Science Advisors, LLC | 2,717,106 | $34.6M | 3.9% | +625,000 |
| Bvf Inc/il | 2,350,000 | $29.9M | 0.8% | New |
| Ra Capital Management, L.P. | 2,332,457 | $29.7M | 0.3% | New |
| Point72 Asset Management, L.P. | 1,173,396 | $14.9M | 0.0% | New |
| Opaleye Management Inc. | 931,000 | $11.9M | 1.1% | −325,228 |
| Logos Global Management LP | 800,000 | $10.2M | 0.4% | New |
| SummitTX Capital, L.P. | 733,774 | $9.3M | 0.2% | New |
| Vanguard Capital Management LLC | 518,803 | $6.6M | 0.0% | +212,402 |
| Ikarian Capital, LLC | 430,000 | $5.5M | 0.9% | New |
| Woodline Partners LP | 286,212 | $3.6M | 0.0% | New |
| American Century Companies Inc | 272,752 | $3.5M | 0.0% | +253,982 |
| Sanofi | 244,083 | $3.1M | 0.6% | No change |
| Acorn Capital Advisors, LLC | 216,171 | $2.8M | 0.8% | −98,881 |
| Renaissance Technologies LLC | 179,600 | $2.3M | 0.0% | −27,315 |
| Jane Street Group, LLC | 162,747 | $2.1M | 0.0% | +97,148 |
| Monimus Capital Management, LP | 132,036 | $1.7M | 0.4% | −2,274 |
| Boothbay Fund Management, LLC | 130,427 | $1.7M | 0.0% | New |
| Geode Capital Management, LLC | 122,690 | $1.6M | 0.0% | +4,538 |
| Citadel Advisors LLC | 120,663 | $1.5M | 0.0% | +105,182 |
| BlackRock, Inc. | 118,507 | $1.5M | 0.0% | +32,360 |
| Marshall Wace, Llp | 67,045 | $854.2K | 0.0% | +14,605 |
| Vanguard Fiduciary Trust Co | 66,217 | $843.6K | 0.0% | +16,222 |
| Carlyle Group Inc. | 60,363 | $769.0K | 0.0% | −1,042,378 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARQ32 Bio Inc. filings on SEC EDGAR
- 2SEC EDGARQ32 Bio Inc. filings on SEC EDGAR
- 3SEC EDGARQ32 Bio Inc. 10-K for fiscal 2025
- 4SEC EDGARQ32 Bio Inc. 10-K for fiscal 2019
- 5SEC EDGARQ32 Bio Inc. 10-K for fiscal 2020
- 6SEC EDGARQ32 Bio Inc. 10-K for fiscal 2021
- 7SEC EDGARQ32 Bio Inc. 10-K for fiscal 2022
- 8SEC EDGARQ32 Bio Inc. 10-K for fiscal 2023
- 9SEC EDGARQ32 Bio Inc. 10-Q for fiscal 2026
- 10SEC EDGARQ32 Bio Inc. 10-Q for fiscal 2026
- 11
- 12
- 13SEC EDGARLee Kalowski, President
- 14
- 15
- 16
- 17
- 18SEC EDGARJulie Jordan, Chief Medical Officer
- 19SEC EDGARCharles Michaud Jr., Officer
- 20SEC EDGARPaul Alloway, Officer
- 21SEC EDGARGabriel Cohn, Chief Medical Officer
- 22
- 23SEC EDGARTimothy P. Kelly, Officer
- 24SEC EDGARDavid S. Grayzel, Board member
- 25SEC EDGARDiyong Xu, Board member
- 26SEC EDGARIsaac Manke, Board member
- 27SEC EDGARKathleen Laporte, Board member
- 28SEC EDGARMark T. Iwicki, Board member
- 29SEC EDGARSven Ante Lundberg, Board member
- 30SEC EDGARAlbert Seymour, Board member
- 31SEC EDGARJeffrey Poulton V., Board member
- 32SEC EDGARAlise Reicin, Board member
- 33SEC EDGARCameron Wheeler, Board member
- 34SEC EDGARJames E. Flynn, Board member
- 35SEC EDGARKush Parmar, Board member
- 36SEC EDGARMahendra Shah, Board member
- 37SEC EDGARMary Thistle, Board member
- 38SEC EDGARRichard J. Gregory, Board member
- 39